Project Grant HT9425261E165
- Federal Grant Award Summary Massachusetts General Hospital (MGH) received a $165,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025 through August 31, 2027. The award supports research mapping drug-sensitive gene expression profiles to spatial patterns of heterogeneity in a mouse model of schwannoma. This research initiative advances the Defense Health Agency's mission to transform healthcare...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Massachusetts General Hospital (MGH) $771,627 under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Tune and Strike Targeting of Glioblastoma." The award, effective August 1, 2025 through July 31, 2027, supports advanced biomedical research aimed at developing innovative therapeutic approaches for glioblastoma, a critical health challenge relevant to military...
- Federal Grant Award Summary Massachusetts General Hospital (MGH), doing business as The General Hospital Corporation, received a $1,385,292 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2025 through August 14, 2028. The grant supports research focused on ex vivo preservation for vascularized composite allotransplantation (VCA) with emphasis on making tolerance induction protocols clinically...
- Federal Project Grant Award Summary The Defense Health Agency awarded Massachusetts General Hospital (MGH) a $382,381 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research on genetic immunodetection and treatment of vascularized composite allograft (VCA) rejection. MGH's Research Management Division, leveraging the institution's substantial biomedical research infrastructure and...
- Federal Grant Award Summary The Defense Health Agency awarded Massachusetts General Hospital a $1.67M project grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025 through August 31, 2029. The award funds development of machine learning-based individualized cardiovascular dose-response models with application to novel clinical decision support systems and population-based analysis. This research initiative represents translational work...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Massachusetts General Hospital $992,302 through the Military Medical Research and Development program (CFDA 12.420) on September 15, 2025, to support a three-year research project titled "Targeting MHCII Ubiquitination to Induce Immune Regulation in Vascularized Composite Tissue Transplantation." The project, which concludes on September 14, 2028, focuses on advancing biomedical research aimed at transforming...
- Federal Grant Award Summary The University of Massachusetts Medical School (UMMS) received a $836,992 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The award, effective August 1, 2025, through July 31, 2028, supports hypothesis-driven biomedical research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Massachusetts General Hospital (MGH) a $1.35M Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025 through June 30, 2029. The award funds research investigating metabolites and metabolic pathways in relation to Crohn disease risk, with research activities conducted at MGH's Boston, Massachusetts location. This biomedical research initiative aligns with the DHA's...
- Federal Grant Award Summary The Defense Health Agency awarded a $1,155,518 Project Grant to Massachusetts General Hospital (The General Hospital Corporation) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. The award supports research into in vivo neuroepigenetics in combat veterans with repeated blast exposure, addressing a critical military health priority within the Defense Health Agency's portfolio of basic,...
- Summary of Federal Project Grant Award The University of Massachusetts Medical School received a $952,162 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2027. The award supports the development of novel, improved adeno-associated virus (AAV) vectors for the treatment of amyotrophic lateral sclerosis (ALS). Research activities will be conducted at the institution's...
The Defense Health Agency awarded Massachusetts General Hospital (MGH) a $839,954 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026 through May 31, 2028. This award funds research and development services for "Augmented Immunomodulatory and Neuroprotective Allogeneic B Cell Therapy for ALS," a two-year initiative focused on advancing therapeutic approaches for amyotrophic lateral sclerosis (ALS). MGH will deliver translational research services through its Research Management Division in Boston, Massachusetts, leveraging the institution's established expertise in neuroscience research and clinical translation to develop and evaluate innovative cell-based therapeutic interventions. The Military Medical Research and Development program supports hypothesis-driven biomedical research designed to transform healthcare delivery for military service members and the American public through innovative medical solutions. As a premier academic medical research institution with substantial federal research credentials, MGH brings institutional capacity in therapeutic development, clinical evaluation, and translational research bridging laboratory discoveries with clinical applications. This award aligns with the program's emphasis on neurodegenerative disease research and represents a continuation of MGH's portfolio of defense and civilian agency-funded research across multiple scientific domains.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $840.0k | 5/18/26 |